Clinical Trials

95 enrolled

Prostatic Neoplasms

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07103018 2026-03-16

STRIKE-001

144 enrolled

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT03523442 2026-03-13

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

19 enrolled

Prostatic Neoplasms

NCT04577833 2026-03-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04644770 2026-03-13

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

144 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04662580 2026-03-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT05022849 2026-03-13

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

15 enrolled

Prostatic Neoplasms

NCT07082920 2026-03-13

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

140 enrolled

Prostatic Neoplasms

NCT07319871 2026-03-13

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

40 enrolled

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT07468396 2026-03-12

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

65 enrolled

Prostatic Neoplasms

NCT06533059 2026-03-09

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

BreastGenitourinaryGynecologic

110 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04221542 2026-03-06

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

479 enrolled

Bites and Stings, Prostatic Neoplasms

NCT06104449 2026-03-06

MK-5684-005

6 enrolled

Prostatic Neoplasms

NCT07114601 2026-03-06

OMNIRAY

BreastGastrointestinalGenitourinaryGynecologic

421 enrolled

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

10 enrolled

Prostatic Neoplasms

NCT06257264 2026-03-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

258 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

78 enrolled

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Vaccinia, Colorectal Neoplasms

NCT05997615 2026-02-24

AMX-500

390 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07236112 2026-02-23

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT06450106 2026-02-19

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

18 enrolled

Prostatic Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

240 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05800665 2026-02-18

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

210 enrolled

Prostatic Neoplasms

NCT07339267 2026-02-18

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

12 enrolled

Prostatic Neoplasms

NCT04397276 2026-02-17

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

82 enrolled

Neoplasms, Prostatic Neoplasms

NCT06136598 2026-02-17

MK-5684-001

14 enrolled

Prostatic Neoplasms

NCT04898634 2026-02-13

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

216 enrolled

Prostatic Neoplasms

NCT06778863 2026-02-13

GUARDIAN-101

BreastGenitourinaryGynecologicHead & NeckThoracic

90 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms

NCT06238479 2026-02-11

EXCEED

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

490 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06440005 2026-02-11

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinarySarcoma

80 enrolled

Breast Neoplasms, Hemangiosarcoma, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT05787587 2026-02-09

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

216 enrolled

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related, Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

174 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06067841 2026-02-04

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

140 enrolled

Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07214961 2026-02-04

ARTISAN

80 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT07174063 2026-01-30

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

15 enrolled

Prostatic Neoplasms

NCT06555796 2026-01-26

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

50 enrolled

Prostatic Neoplasms

NCT06465069 2026-01-22

NEXUS-01

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

420 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT07358806 2026-01-22

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

BreastGenitourinaryHead & NeckThoracic

51 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms

NCT05519449 2026-01-20

ENGAGER-PSMA-01

272 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06751329 2026-01-15

A Study of DM002 in Patients With Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologic

160 enrolled

Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07344311 2026-01-15

A Phase I Trial of A-CAR032 in Participants With mCRPC

27 enrolled

Prostatic Neoplasms

NCT06781983 2026-01-07

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

145 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06840535 2026-01-06

OncoACP-3

20 enrolled

Prostatic Neoplasms

NCT06545942 2025-12-23

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

220 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04428788 2025-12-22

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

131 enrolled

Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06229366 2025-12-22

ACCEL

142 enrolled

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT06613100 2025-12-01

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

40 enrolled

Prostatic Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

120 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03792841 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Phase 1 Terminated

212 enrolled